Genmab — August 2020
-
Vi fik tidlige top line data på epcoritamab før ASCO. Så hvis PD-L1x4-1BB præsenteres på medical conference, så er det måske muligt med tidlige topline data?
-
Den 13 maj kom der topline data på epcoritamab i forbindelse med ASCO abstracts. Det var godt 2 uger før ASCO.
-
Embargoen løftes og abstracts offentliggøres 9. november. Abstract-TITLER hhv regular og LBa offentliggøres hhv 14. okt og 2. nov. https://www.sitcancer.org/2020/abstracts/abstract-information#dates
-
-
-
God morgen.
-
-
M.h.t. TV 204 på ESMO, så gjorde han en del ud af dette på Q&A I går, bl.a.: "We very much look forward to discussing these results with the FDA and the potential for the first BLA submission for one of our proprietary therapeutic candidates, which would be an important milestone in our company’s history.."
-
Genmab News - Phase 2 innovaTV 204 study results accepted as a late-breaking abstract at the ESMO Virtual Congress, 2020. Oral presentation is at 17:04 CEST on Sep 21, 2020.
http://ow.ly/gdxj50Ba5F7
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind